Progression Independent of Relapse Activity in Pediatric-Onset MS
Pediatric-onset multiple sclerosis (MS) patients showed progression independent of relapse activity (PIRA) even when they were relatively young, a prospective cohort study found. Confirmed PIRA events within 48 weeks of baseline occurred in 40.4% of pediatric-onset MS patients and were more frequent in older-onset groups, reported Maria Pia Amato, MD, of the University of Florence […]
CPAP Turns in Mixed Results for Patients With Diabetic Eye Disease
Long-term use of continuous positive airway pressure (CPAP) slowed the progression of eye disease in sleep apnea patients with non-proliferative diabetic retinopathy, a small randomized study showed, but patients who adhered to the intervention ended up with more retinal microhemorrhages. In the single-center trial, the group assigned to a year of CPAP atop usual care […]
Donanemab Slows Progression in Early Alzheimer’s
AMSTERDAM — Investigational donanemab significantly slowed clinical progression at 76 weeks in people with early symptomatic Alzheimer’s disease who had amyloid and tau pathology, the phase III TRAILBLAZER-ALZ 2 trial showed. The drug, which targets a modified form of beta amyloid known as N3pG, showed significant slowing versus placebo on measures of cognition and daily […]
Multimodal Evaluations May Flag Cardiac Allograft Problems Earlier
Coronary anatomy and physiology both predicted early cardiac allograft vasculopathy (CAV) progression, according to a study that strengthens the case for advanced multimodal testing to improve early detection of a major contributor to allograft failure. Among heart transplant recipients at two Canadian centers, early progression of percent intimal volume (PIV) on intravascular ultrasound (IVUS) between […]
Cervical Cord Atrophy Predicts Silent MS Progression
Spinal cord atrophy predicted disease progression in people with relapsing multiple sclerosis (MS), a single-center observational study showed. A 1% faster cervical cord atrophy rate was associated with 69% (P<0.0001) shorter time to silent clinical progression and a 53% (P<0.0001) shorter time to secondary progressive MS (SPMS) conversion, reported Antje Bischof, MD, of University Hospital […]
Two PARP Inhibitors Impress as First-Line Add-Ons in mCRPC
Adding PARP inhibition to first-line abiraterone (Zytiga) reduced the risk of radiographic progression or death in metastatic castration-resistant prostate cancer (mCRPC), a pair of phase III studies showed. In PROpel, patients who received olaparib (Lynparza) along with abiraterone plus prednisone had a roughly 8-month improvement in median radiographic progression-free survival (rPFS) versus those assigned placebo […]
Researchers lay groundwork for potential dog-allergy vaccine
There have been many research efforts describing the nature and progression of dog allergies, but there have been very few applied studies that use this information to try to cure people of dog allergies entirely by artificially inducing immune tolerance. But researchers have now for the first time identified candidates for those parts of the […]
Antibiotics Slow Down Latent Rheumatic Heart Disease in Kids
Antibiotic prophylaxis for screen-detected latent rheumatic heart disease reduced progression of disease in children, the GOAL trial showed. Echocardiographic progression was reduced to 0.8% at 2 years compared with 8.2% with no prophylaxis (P<0.001), reported Andrea Beaton, MD, of Cincinnati Children’s Hospital Medical Center, at the American Heart Association virtual meeting. The findings were simultaneously […]
Finerenone OK’d for Slowing Kidney Disease in T2D
The FDA approved the anti-mineralocorticoid agent finerenone (Kerendia) for slowing the progression of chronic kidney disease in type 2 diabetes patients, the agency announced on Friday. The first non-steroidal, selective mineralocorticoid receptor antagonist was approved to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, […]